Neuronal network disintegration: common pathways linking neurodegenerative diseases

Rebekah M Ahmed,1,2 Emma M Devenney,1,2 Muireann Irish,2,3 Arne Ittner,4 Sharon Naismith,5 Lars M Ittner,4 Jonathan D Rohrer,6 Glenda M Halliday,2 Andrew Eisen,7 John R Hodges,2 Matthew C Kiernan1

ABSTRACT

Neurodegeneration refers to a heterogeneous group of brain disorders that progressively evolve. It has been increasingly appreciated that many neurodegenerative conditions overlap at multiple levels and therefore traditional clinicopathological correlation approaches to better classify a disease have met with limited success. Neuronal network disintegration is fundamental to neurodegeneration, and concepts based around such a concept may better explain the overlap between their clinical and pathological phenotypes. In this Review, promoters of overlap in neurodegeneration incorporating behavioural, cognitive, metabolic, motor, and extrapyramidal presentations will be critically appraised. In addition, evidence that may support the existence of large-scale networks that might be contributing to phenotypic differentiation will be considered across a neurodegenerative spectrum. Disintegration of neuronal networks through different pathological processes, such as prion-like spread, may provide a better paradigm of disease and thereby facilitate the identification of novel therapies for neurodegeneration.

INTRODUCTION

Considerable debate exists regarding neurodegeneration, an umbrella term that incorporates a wide range of neurological disorders with heterogeneous clinical and pathological expressions affecting distinct subsets of neurons in specific functional anatomical systems showing a relentless progression.1 Traditionally, the study of neurodegenerative disorders has relied on a conventional clinicopathological approach, defining a particular clinical diagnoses (such as Alzheimer’s disease), and attempting to match this to a pattern of pathology in the brain. However, it is increasingly recognised that there is considerable clinical and pathological overlap across neurodegenerative disorders (figure 1). Patients with frontotemporal dementia (FTD) may present with amyotrophic lateral sclerosis (ALS) and vice versa;2 patients with parkinsonism plus syndromes (including corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) phenotypes) may present with initial cognitive changes,4 while patients with FTD may develop prominent extrapyramidal symptoms resembling parkinsonian plus syndromes.3 Pathologically, there appears to be limited correlation linking specific syndromes such that both tau and Tα-43 pathology can result in behavioural variant FTD (bvFTD),2 while corticobasal syndrome (CBS) may be associated with both CBD and Alzheimer’s disease pathology.1 As such, current clinicopathological approaches fail to recognise the heterogeneity of these conditions.

An alternative approach to the classification of neurodegenerative disorders invokes neural networks, defined as a series of interconnected neural nodes that determine physiological function.5 7 These networks occur at microscopic (neurons and synapses), macroscopic or structural (anatomical regions and fibres), and functional (physiological connections) levels.8 There is a wealth of literature describing specific networks based on functional and structural imaging modalities.8 More recently, the concept of pathological networks based on pathogenic proteins, known as ‘molecular nexiopathies’,8 has been developed. It has been suggested that the susceptibility and phenotype will vary contingent on the involvement of specific neural networks.7 In this Review the overlap between neurological conditions in terms of clinical phenotype (behaviour, cognitive, primary motor, extrapyramidal, and metabolic) rather than syndromic diagnoses will be discussed, and the evidence suggesting widespread network involvement in neurodegeneration will be critically appraised. Network involvement in neurodegenerative language disorders will not be discussed, but extensive reviews are available.9 Evidence for network dysfunction at a genetic and pathological level, and how neurodegeneration may spread along these networks in a prion-like manner will be discussed in addition to transgenic mouse models that may play a role in mapping network involvement across neurodegenerative disorders.

Clinical phenotypes and neurodegeneration

Behavioural phenotypes in neurodegeneration

Behavioural changes have been associated with a range of clinicopathological diagnoses, but are most characteristic of bvFTD, as reflected in current diagnostic criteria. Patients with bvFTD typically present with changes in behaviour ranging from apathy − with reduced motivation, inertia, and a lack of interest in previous hobbies − to disinhibition manifesting in impulsive and often socially inappropriate actions such as overspending, gambling, or sexually inappropriate remarks. Mental rigidity and stereotypical behaviour is also widely
Neurodegeneration

reported by caregivers, leading to alterations in food preferences and eating behaviour. Similar, prominent behavioural symptoms have been recorded in other neurodegenerative disorders, including ALS and a number of parkinsonian plus syndromes that display significant overlap with FTD. Patients with ALS may develop prominitent behavioural features including apathy, loss of empathy, emotional lability, and less commonly gluttony, behavioural stereotypes and compulsions. Patients with ALS may occasionally develop neuropsychiatric and behavioural stereotypes and compulsions. Patients with ALS and a number of parkinsonian plus syndromes that display significant overlap with FTD.2 Patients with ALS may develop prominent behavioural features including apathy, loss of empathy, emotional lability, and less commonly gluttony, behavioural stereotypes and compulsions. Patients with ALS may occasionally develop neuropsychiatric and behavioural symptoms prior to the onset of classic motor symptoms.10 In a number of parkinsonian plus syndromes, such as PSP and CBS, there is increasing evidence for prominent behavioural change, including apathy,11 12 impaired social engagement,12 and impaired emotional expression.13 It has recently been suggested that behavioural changes may be present in up to 30% of patients with PSP.3 Patients with CBS and the language variants of FTD (semantic dementia) also develop difficulties with behaviour and emotion processing.14 Given the clinical overlap seen in behaviour and emotion processing in these disorders, it is likely that commonalities exist in the disruption or dysfunction of networks controlling these phenotypic behaviours.

Neural networks and behaviour

The last decade has witnessed a surge of evidence proposing dysfunction within large-scale neural networks; these relate to resting state and intrinsic connectivity functional MRI (fMRI), EEG and MEG studies that correlate with clinical presentations of abnormal behaviours in neurodegenerative diseases. Three major networks have been associated with aberrant behaviours in neurodegenerative diseases—the salience network (SN), the default mode network (DMN) and the executive-control network (ECN).

The SN is centred on the dorsal anterior cingulate cortex (dACC) and frontoinsular cortex with extensive links to both cortical and subcortical regions, including the superior temporal pole, the dorsolateral prefrontal cortex, the amygdala, thalamus, hypothalamus, and the substantia nigra/ventral tegmental area.15 In terms of behaviour, the SN is implicated in detecting, analysing, and integrating emotionally salient stimuli with respect to the internal environment.15 Within the network, the anterior insula is involved in salience detection, whereas the anterior cingulate functions as a modulator of behaviour. The anterior insula, together with the extended SN and input from the posterior insula, integrates internal sensory stimuli to produce a socially appropriate behavior, for example, wearing appropriate clothing for the season. Not only is the insula activated during internal sensory stimuli, it also shows activation to external emotionally salient stimuli such as love, compassion, empathy, disgust, anger, and happiness.16

While the SN is critical for self-awareness, self-control and emotion regulation, it also has a modulatory effect on the DMN—another large-scale network involved in behaviour and cognition (including autobiographical memory, prospection, and theory of mind) and intrinsically linked to the ECN.17 The DMN comprises a network of brain regions with core regions in the posterior cingulate cortex (PCC), lateral parietal cortex and medial prefrontal cortex (mPFC), and prominent connections to nodes in the medial temporal lobe (MTL) and angular gyrus. The DMN is reciprocally deactivated during attention-demanding tasks which activate the SN. In contrast, a number of specific non-stimulus driven cognitive functions activate the DMN; autobiographical memory, and episodic memory are associated with activation of nodes in the PCC, while theory of mind and moral reasoning are associated with activation of specific nodes in the mPFC.18 19 The reciprocity of DMN and SN activation in moral reasoning exemplifies the role of the anterior insula in modulating behaviour by switching between large-scale networks.20 As mentioned, the DMN is activated in healthy participants during moral reasoning tasks; however, during these tasks there is also directed functional connectivity to nodes within the SN. This functional connectivity between the DMN and SN is diminished when patients with FTD show poor moral reasoning.21 Finally, the ECN links the dorsolateral frontal and parietal neocortices as well as the dorsal caudate and anterior insula, and is primarily involved in manipulating and maintaining information in working memory, sustained attention, response selection to goal-directed behavior, and inhibition.15 22 Depending on the task, the ECN and the DMN show antagonistic responses. For example, when a participant is involved in an attention-demanding task in which self-referential and episodic memory is unnecessary, then the ECN is engaged and the DMN is disengaged,23 network changes that are facilitated by the SN and in particular, the anterior insula.

Common neural networks for the behavioural phenotype in neurodegeneration

As mentioned previously, many abnormal behaviours (including apathy and poor social interactions) are pervasive among an array of neurodegenerative conditions (including ALS, FTD, PSP, CBD and AD). Although these conditions show a variety of clinical phenotypes with distinctive neuroanatomical, neuroimaging, and genetic signatures, their shared behavioural deficits could be explained in terms of network disruption.

Mounting evidence exists for involvement of the SN in FTD, particularly in relation to bvFTD.24 These findings converge with results from structural imaging studies which demonstrate atrophy of key regions of the SN, including the anterior cingulate cortex, insula and subcortical structures (including the amygdala, striatum and thalamus), all regions which have been implicated in complex social and emotional processing.25 Furthermore, reduced SN connectivity correlates with disease severity.26 27 Considering the role of the SN and in particular, the anterior cingulate in terms of behaviour modulation, it is not surprising that patients with abnormalities in this network, and particularly patients with FTD, show profound disinhibited behaviour with loss of social graces and reduced empathy. In
contrast, studies of DMN connectivity in FTD have shown conflicting results that perhaps can be reconciled in light of the top-down influence of the SN on the DMN, as discussed above. Theory of mind deficits are intrinsically linked to autobiographical memory and prospection through connectivity in the mPFC of the DMN in healthy participants. Deficits in ‘theory of mind (ToM)’ are often profound in FTD; these patients are unable to imagine the thoughts and experiences of others, and are often unsympathetic to issues which do not concern themselves and these, in turn, can cause conflict within personal relationships. Deficits in ToM have also been identified in patients with ALS and PSP, thus supporting the hypothesis that these conditions merge in terms of abnormalities in the DMN. In AD, the DMN consistently shows reduced connectivity, and this again corresponds to atrophy patterns in AD and has been shown to predict disease severity and progression. Similarly, the relative preservation or intensification of SN activation is in parallel with the preservation of manners and social decorum until late in AD, but has been shown to be associated with aberrant motor behaviour, anxiety, and irritability.

In comparison, patients with ALS have shown inconsistent results in terms of network connectivity. A number of theories arise in terms of resolving the conflict between studies. The first enhanced connectivity may occur in ALS due to loss of cortical inhibition, and is in keeping with findings from one study that found a greater rate of disease progression in those with the most functional connectivity; the second that enhanced functional recruitment may occur in one region to compensate for loss of function in another, a compensatory mechanism that is early and may be lost as the network disintegrates and cognitive deficits increase. Finally, the heterogeneity of the ALS phenotype, particularly in terms of cognitive and behavioural features, may influence and be influenced by the pattern of network degeneration.

Further insights may be gained by exploring the complex interactions within and between large-scale neural networks in PSP and CBS, which show overlapping behavioural abnormalities and structural changes with FTD. The network degeneration theory has been confirmed in CBS, but as yet no published data exists regarding the nature of intrinsic connectivity abnormalities in these disorders in relation to behavioural changes.

Cognitive phenotype in neurodegeneration

Episodic memory dysfunction represents a hallmark feature of AD with patients typically experiencing difficulties in the encoding and retrieval of recently experienced events. Irrespective of the domain of testing, patients with AD display significant impairments on standard neuropsychological tests of visual and verbal recall, as well as gross impairments in the retrieval of personally relevant autobiographical memories from their past and adaptive forms of memory such as prospective memory. The MTL represent one of the earliest sites of pathology in AD, leading to the common assumption that episodic memory impairment reflects MTL dysfunction. It is evident, however, that regions beyond the MTL, such as the PCC/retrosplenial cortex, also play a crucial role in the origin of memory dysfunction in AD. It has been argued that disruption of functional connectivity between the hippocampus and posterior parietal regions represents a key modulator of episodic memory disruption in AD.

While memory dysfunction is regarded as a phenotypic feature of AD, mounting evidence points to significant episodic memory disturbance in other neurodegenerative disorders, thus suggesting that the diagnostic utility of traditional neuropsychological memory tasks may be more limited. For example, a severe amnestic presentation remains an exclusion criterion for the diagnosis of bvFTD; yet a number of studies converge to reveal striking memory impairments equivalent to that of matched cases of AD. These deficits occur irrespective of the domain of testing of the standardised tests for verbal and visual, immediate and delayed, recall, autobiographical memory and prospective memory. Further impairments are evident for source memory, with bvFTD cases unable to correctly retrieve the spatial or temporal context of previously presented items. Given that the locus of atrophy in FTD typically affects frontoinsular cortices, it was initially assumed that episodic memory difficulties in bvFTD reflected prefrontal cortical degeneration. Recent studies unequivocally point to the involvement of MTL, notably the hippocampus, in driving episodic memory deficits in bvFTD. Accordingly, it is clear that significant overlap exists in the neural circuitry mediating episodic memory deficits in bvFTD and AD, with the hippocampus representing a critical nexus in this system.

Common neural networks for the cognitive phenotype in neurodegeneration

The advent of sophisticated neuroimaging techniques has served to clarify the complexity of the neural circuitry which supports episodic memory in humans, confirming that engagement of a distributed network of cortical regions exhibiting strong connections with the MTL is essential for episodic memory retrieval. Key cortical regions in this network include frontal regions such as the medial prefrontal cortex as well as posterior parietal structures, including the retrosplenial/PCC and the angular gyrus. The hippocampus appears particularly well placed to support episodic memory retrieval given its dense projections with prefrontal and midline posterior cortical structures. In addition, subcortical structures, such as the thalamus and fornix, are becoming increasingly recognised for their role in supporting episodic retrieval, further underscoring the complexity of this system. Damage to any node of this large-scale network or alterations in the functional connectivity therein will result in compromised memory performance, as evident in the large-scale network dysfunction observed in the dementias.

Primary motor/extrapyramidal phenotype and cognition in neurodegeneration

The archetypical overlap syndrome between loss of primary motor function and cognition is that of FTD and ALS. Symptoms of cognitive dysfunction and FTD can occur in ALS, and patients with FTD can develop limb weakness and bulbar dysfunction. There is also increasing awareness of an overlap in clinical phenotyping between extrapyramidal symptoms, including parkinsonism, bradykinesia, rigidity and gait abnormalities, and cognitive changes within the parkinsonian plus syndromes; in other words, it is often difficult to separate a diagnoses of FTD (behavioural and language variants) from CBS and PSP. Patients can often present with any of these movement disorders and go on to develop cognitive symptoms, most commonly in the form of behavioural change. Presentation may be with cognitive deficits and also involve other domains, including aphasia, apraxia of speech, limb apraxia, and visuococonstructive deficits. Further complicating the issue is that patients with different genetic causes of FTD, including the C9orf72 expansion, microtubule associated protein tau (MAPT) and progranulin (GRN) mutations, can develop features of parkinsonism,
Neurodegeneration

with both MAPT and progranulin mutations in particular being associated with CBS and PSP.

Common neural networks for the primary motor/extrapyramidal phenotype in neurodegeneration

Structural and functional imaging studies have indicated that networks involved in the primary motor deficits of ALS functionally and anatomically involve regions associated with the motor cortices. On diffusion tensor imaging the corpus callosum has been found to be consistently affected in ALS; the hypothesis is that it is integral for the pathological spread in the brain. Voxel-based morphometry shows atrophy of motor cortices occurs in the primary motor phenotypes of both FTD and ALS, with additional atrophy also found in the left middle and inferior frontal gyri, the anterior portion of the superior frontal gyri, the superior temporal gyri, the temporal poles and the left posterior thalamus, and the non-motor regions known to be involved in pure bvFTD. This broader pattern of atrophy potentially explains the spectrum of motor and cognitive changes seen across FTD and ALS.

The extrapyramidal symptoms associated with parkinsonian plus syndromes differ depending on the clinical syndrome. Atrophy in PSP is localised to the midbrain, pons, thalamus and striatum; in CBS, bilateral atrophy of the premotor cortex, superior parietal lobules, and striatum occurs. It has been suggested that PSP participants with an extrapyramidal syndrome have more brainstem atrophy and less cortical atrophy than CBS participants. Studies examining network connections in PSP using white matter tract diffusion tensor imaging and functional MRI, found disruption of network connectivity between the cerebellum, midbrain, thalamus, and premotor cortex. It has been suggested that PSP is associated with disrupted thalamocortical connectivity and the dentatorubrothalamic tract. An alternative study has suggested involvement of a network anchored by the dorsal midbrain and with connections including the brainstem, basal ganglia, diencephalic, cerebellar and cortical regions. A network such as this could potentially explain the mixed motor, behavioural and cognitive features observed in PSP. Further studies have suggested that white matter tract degeneration differs between PSP, Parkinson’s disease, multisystems atrophy, and CBS. Studies of overlap in networks responsible for the extrapyramidal symptoms in PSP, CBD and FTD have been limited, but such network overlap is likely given the strong clinical overlap between these conditions. Further research involving structural and functional imaging across these disorders would prove to be fruitful.

Metabolic phenotype in neurodegeneration

Recently it has been suggested that the overlap in neurodegenerative diseases may extend beyond motor and cognitive features, and involve more systemic bodily functions such as metabolism. Insulin resistance and type 2 diabetes appear to play an important role in modulating neurodegenerative diseases; an increased incidence of peripheral insulin resistance and diabetes is identified in a number of neurodegenerative conditions, including AD, Parkinson’s disease, Huntington’s disease ALS and FTD. How insulin promotes neurodegeneration remains unclear, but it may exert a peripheral and central influence. Proposed mechanisms include the promotion of oxidative stress, inflammation, vascular dysfunction, and impairment of neurogenesis and neuronal repair. Typically, insulin resistance and metabolic changes have been viewed as consequences of obesity. Mounting evidence indicates, however, that several neurodegenerative conditions – including AD, Huntington’s disease and ALS – are associated with significant weight loss, often prior to diagnosis, implying that these metabolic changes may be part of the neurodegenerative process rather than a consequence of obesity. Further, metabolic change may underlie phenotypic changes in behavior, such as in bvFTD, where patients develop prominent changes in eating behaviour with hyperphagia and changes in food preference. This could have a subsequent effect on insulin and cholesterol levels.

Common neural networks for the metabolic phenotype in neurodegeneration

There is increasing evidence for networks controlling eating behavior, and neuroendocrine control and metabolism in conditions such as bvFTD, with involvement of reward networks, the hypothalamus and changes in neuroendocrine peptides. At a pathological and imaging level, other neurodegenerative conditions show changes in the neuroendocrine system, including ALS and Huntington’s disease; these are conditions exhibiting hypothalamic atrophy. Further work is required to map the neural networks in neurodegeneration that influence behavioural change and metabolism directly.

Pathology and neurodegeneration

Does pathology correlate better to phenotypic networks than to clinical diagnostic syndromes?

Evidence for involvement of networks in neurodegeneration at a pathological level is growing. Recently, the concept of ‘molecular nexopathies’ proposes that pathological proteinopathies can target specific networks, and multiple functional networks can be targeted by these proteinopathies. This in turn leads to phenotypic variation and potential overlap between these disorders. This model is enticing especially given the hypothesis that proteinopathies may spread in a ‘prion’ like manner. Prions are defined as proteinaceous infectious particles consisting of misfolded prion protein that aggregate together and act as ‘seeds’ that result in a chain reaction causing further misfolding and aggregation, and these spread throughout the central nervous system. A prion hypothesis for disease spread has been hypothesised for a number of neurodegenerative conditions, including amyloid in AD, TDP-43 in FTD and ALS, Tau in Pick’s disease, and PSP and synuclein in Parkinson’s disease.

In terms of the pathological networks corresponding to clinical phenotypic networks (ie, behaviour, cognitive, primary motor, extrapyramidal, and metabolic) this is an emerging area. To date, the examination of pathological networks has been based around the traditional clinical diagnostic syndromes (eg, Alzheimer’s disease) rather than on the phenotypic networks highlighted above. The most developed pathological networks in terms of correlation to clinical phenotypic networks involve the β-amyloid and TDP-43 proteins, with tau an emerging area of research.

β-amyloid and the cognitive network

In AD it has been hypothesised that β-amyloid spreads in prion-like manner giving different pathological stages of β-amyloid deposition. β-amyloid first accumulates in the basal temporal and orbitofrontal neocortex, then spreads throughout the neocortex and then to the hippocampi, amygdala, diencephalon and basal ganglia. Then finally, in severe cases, this spreads to the mesencephalon, lower brainstem, and cerebellar cortex. How this pathological spread interacts with clinical phenotypic networks remains to be elucidated. There is emerging research examining this with β amyloid being found to preferentially
deposit in the DMN network and higher order intrinsic connectivity networks, including the frontoparietal network, with areas showing decreased functional activity including both areas exhibiting β-amyloid deposition and atrophy.77 Frequently, however, in AD there is a disparity between the presence of pathology (eg, β-amyloid) and functional impairment.78 A recent study examined the functional impairment between variants of Alzheimer’s disease (early onset, logopenic variant, and posterior cortical atrophy) as measured by 18F-labelled fluorodeoxyglucose positron emission tomography (FDG-PET), and β-amyloid deposition as measured by (11)C-labelled Pittsburgh compound B.78 It was found that the AD variants had degeneration in specific functional networks, while their pattern of β-amyloid deposition varied, often being diffuse.78 This suggests that the location of β-amyloid deposition may not fit the network patterns involved in the clinical variability seen between AD syndromes.79 Further work is required to understand the interaction between clinical phenotypic networks, and deposition of pathology along these networks and more diffusely.

TDP-43 and the primary motor and behavioural networks
In ALS it has been suggested that spread of TDP-43 pathology may occur in a recognised centrifugal pattern with four stages of spread.79 TDP-43 accumulation begins in the motor neocortex, progressing to the spinal cord and brainstem with involvement of frontal-parietal regions, and finally to the temporal lobes.79 Such a pattern of spread may potentially explain the eventual development of cognitive symptoms in ALS and the predominant clinical phenotype of motor signs. In bvFTD, TDP-43 pathology is suggested to develop with a frontooccipital gradient involving initial accumulation in frontal regions, then premotor, primary motor, parietal and occipital cortices.80 This pattern of pathological spread explains the initial prominent behavioural changes followed by involvement of other cognitive functions as the disease progresses.80

Tau Pathology and networks
Neuronal tau pathology networks have been described in AD with neuronal tau inclusions developing in the locus coeruleus, as well as in the transentorhinal and entorhinal cortices (stages I and II). This is followed by the presence of neuronal tau inclusions in the hippocampal formation and some parts of the neocortex (stages III and IV), followed by large parts of the neocortex (stages V and VI).84 How these stages relate to differing clinical phenotypic networks has not been examined, nor has the relationship between phenotypic networks and the glial tau pathologies of CBD and PSE.

How transmission occurs along pathological networks
There is growing evidence from animal models that transmission may occur in a prion-like fashion along neurons connected in networks. A recent study shows that injection of human brain extracts from patients suffering different tauopathies (including AD, Pick’s disease, PSE and CBD) resulted in the formation of tau inclusions in ALZ17 transgenic mice.81 Similar attempts were trialled several decades ago by Cajal and others in mice with limited success.82 Hypotheses of how cell-to-cell transmission occurs varies between diseases, with suggestions that include trans-synaptic transmission, transmission through membrane channels, and glial cell intrusions into neurons.83 84

In ALS it has been suggested that transmission between neuronal networks may occur via glia with which endocytose extracellular protein material.85 however, the oligodendrocytes along such connected pathways are unlikely to be involved since they do not accumulate TDP-43 protein.85 In PSP and CBD, with such obvious glial tau pathology, this may be a more dominant mechanism and the tau oligomers are considered as most responsible for the spread of pathology through the brain.86 It is potentially possible that susceptibility of specific cells to specific proteinaceous material may vary, and this along with the susceptibility of various functional networks may be responsible for the heterogeneity of clinical phenotypes as well as their overlap. Why some clinical phenotypic networks (eg, the behavioural network) may be susceptible to several proteins (eg, tau and TDP-43) while the primary motor network, as in ALS, seems more susceptible to only TDP-43 pathology remains elusive. It likely involves genetic, epigenetic and environmental interactions.

Do genetic abnormalities correlate better to phenotypic networks than to pathology and clinical diagnostic syndromes?
Genetic mutations involved in neurodegenerative diseases
A given clinical syndrome is often associated with several different genetic mutations and underlying pathologies. FTD is a good example. There are a wide range of causative genes for FTD, including C9orf72, MAPT and GRN, and other rarer causes including VCP, CHMP2B, FUS, TARBP, DCTN1 and SQSTM1. At a clinical level, C9orf72, MAPT and GRN are all most commonly associated with a bvFTD clinical presentation; however, even though they are associated with a similar clinical picture, C9orf72 and GRN are associated with TDP-43 pathology, while MAPT mutations are associated with underlying tau pathology. The clinical syndrome of pure ALS is also associated with a common clinical presentation, but with variable underlying genetic mutations and pathology. ALS is associated with mutations in SOD1, TARDBP, FUS and GGGGCC expansions in C9orf72. At a pathological level, most cases are associated with TDP-43 pathology.87 SOD-1 mutation cases, however, do not have TDP-43, but have neuronal SOD1 inclusions. CBD and PSP can be associated with MAPT mutations,88 and autosomal dominant AD has been associated with mutations in the Amyloid precursor Protein (APP) and presenilin 1 and 2, with late onset risk associated with allelic variation of apolipoprotein E. How this multitude of genetic mutations can be associated with differing pathologies, but overlapping clinical phenotype is not known; thus, the examination of genetic mutations in relation to network dysfunction may prove to be fruitful.

To date, despite a wealth of literature regarding the relationship between genetic mutations and pathological changes, and specific brain atrophy on imaging, there has been limited examination of the relationship between genetic mutations and either clinical phenotypic functional or pathological networks; however, this is an emerging area. In bvFTD, both C9orf72 mutation carriers and non-carriers showed convergent breakdown of large-scale networks despite different atrophy patterns, with behavioural symptoms correlating with diminished SN connectivity and heightened default node connectivity.89 This area of research will be likely to provide useful insights into the networks underlying neurodegeneration and clinical phenotypic heterogeneity, and will also provide useful insights into the molecular functioning of genes within networks and hence, in therapeutic trials. The mapping of networks in relation to genetic mutations also offers the prospect of being able to examine the network function of presymptomatic carriers and identify network involvement early on in the disease process. It has been found that GRN mutation carriers change decades
before the onset of the disease in functional brain networks that
begin in the parietal region and then spread to the anterior
brain. The relationship between genes and neural networks
will also provide an important link between animal models and
these functional networks as many animal models are based on
a specific genetic mutation.

**Use of mouse models to map networks**

Transgenic mice, and other animal models, have been instrumen-
tal to further our understanding of neurodegenerative diseases.
While the first models used transgene-mediated expression of
human amyloid precursor protein (APP) to model aspects of AD,
other models followed to reflect tauopathies by transgenic
expression of tau, ALS by expression of TDP-43, SOD1 or more
recently through transgenic expansion of C9orf72 repeats.
Neuronal network aberrations and hyperexcitability have been
described for transgenic mouse models using EEG and
imaging. Interestingly, network aberrations and hypersynchronous
discharges and hyperexcitability are detectable in APP
mice preceding notable β-amyloid deposition, and cognitive
deficits in APP transgenic mice are apparent at early stages. The
early involvement of neuronal network abnormalities before
marked pathology reflects findings in human functional imag-
ing studies, and suggests that soluble APP products (eg,
β-amyloid or β-amyloid oligomers) rather than β-amyloid
plaques are involved in the generation of network impairments
and likely cognitive deficits. The animal data also suggests that
network aberrations and hyperexcitability are linked. Key techni-
ques used in mouse models to analyse neuronal network function
are electroencephalography (EEG) and computational methods
to mine EEG data for network performance. Several recording
types appear particularly relevant as their network features can
be related to cognitive performance by computational means.
Hippocampal recordings from the cornu ammonis (CA) region,
for example, provide insight on performance and topology of
pyramidal/interneuronal connections that are reflected in EEG
and theta oscillations and their phase coupling. Spontaneous
and induced hyperexcitability has also been observed in tau trans-
genic mouse models. However, detailed analysis of network
topology by EEG or electrophysiology of single cells in situ in tau
transgenic mice have not been performed. Network alterations in
ALS mouse models using SOD1, TDP-43 overexpression, or
C9orf72 repeat expansion have also not been addressed. Further
research is required into how network aberrations and hyperex-
citability are linked in such disease-relevant animal models.

In addition to functionally studying networks in animal
models, the recent advances in optogenetics have now made
manipulation of neuronal systems in vivo feasible. Combining
functional network analysis by EEG, electrophysiology or
imaging with induced changes in activity of specific neuronal
ensembles using optogenetics could prove to be a valuable tool
to address whether network aberrations can be manipulated or
even reversed by specifically targeting subsets of neurons (eg,
interneurons). Insights from these induced network outputs can
then be correlated with cognitive performance. Mouse models,
therefore, are a past and future tool to test these basic hypoth-
eses on disease-relevant network mechanisms and to help drive
better targeted therapies.

---

**Figure 2** Neurodegenerative network map: proposed way forward for a collaborative approach based on phenotypic variation, imaging, pathology and genetics for investigating the neural networks and their contribution to the pathophysiological bases of neurodegenerative conditions. A better understanding of the neural networks involved is likely to translate into better targeted treatments based on these networks. DTI, diffusion tensor imaging; PET, positron emission tomography.
FUTURE APPROACHES

Based on the available literature, it is proposed that the clinical and pathological heterogeneity of neurodegenerative disorders remains fundamentally related to the functioning of underlying neural networks. Understanding these networks and how they are intrinsically involved will not only advance our clinical understanding of these conditions and their varying phenotypes, but also provide greater insight into their pathophysiology. The standard approach of examining one aspect of these conditions and mapping it to a particular brain region through neuroimaging and pathological examination has met with limited success, perhaps resulting in therapeutic failures. A potential way to overcome this problem would be to take ecologically valid tasks that show changes across multiple neurodegenerative conditions (eg, a task measuring behavioural change) and use multiple imaging techniques – both structural and functional – to map the brain networks in multiple conditions (figure 2) and understand their specific genetic susceptibilities. Using these networks, pathological involvement could be examined in addition to the imaging techniques (eg, a task measuring behavioural change) and use multiple imaging techniques – both structural and functional – to map the brain networks in multiple conditions (figure 2) and understand their specific genetic susceptibilities. Using these networks, pathological involvement could be examined in addition to the neurodegenerative conditions may also be gained by comparing animal models with relevant susceptible genetic mutations for the networks involved. Understanding a neural network of neurodegeneration and patterns of disease spread and progression via such networks seems likely to promote new treatment approaches.

Contributors

RMA and MCK manuscript concept. All authors were involved in the drafting and editing of the manuscript.

Funding

This work was supported by funding to Forefront, a collaborative research group dedicated to the study of frontotemporal dementia and motor neurone disease, from the National Health and Medical Research Council of Australia (NHMRC) programme grant (#1037746 to GH, MK and JH) and the Australian Research Council Centre of Excellence in Cognition and its Disorders Memory Network (CE110001021 JH) and other grants/ sources (NHMRC project grant #1003139). RA is a Royal Australasian College of Physicians PhD scholar and MND Research Australia PhD Scholar. MI is an ARC Discovery Early Career Researcher Award Fellow (D130100463). GH is a NHMRC Senior Principal Research Fellow (#1079679). LSTM is a NHMRC Senior Research Fellow (#1003088). No funding source had a role in the writing of the manuscript.

Competing interests

None declared.

Patient consent

No.

Provenance and peer review

Commissioned; externally peer reviewed.

Access Open

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and to map the brain networks in multiple conditions (figure 2) and understand their specific genetic susceptibilities. Using these networks, pathological involvement could be examined in addition to the neurodegenerative conditions may also be gained by comparing animal models with relevant susceptible genetic mutations for the networks involved. Understanding a neural network of neurodegeneration and patterns of disease spread and progression via such networks seems likely to promote new treatment approaches.

Contributors

RMA and MCK manuscript concept. All authors were involved in the drafting and editing of the manuscript.

Funding

This work was supported by funding to Forefront, a collaborative research group dedicated to the study of frontotemporal dementia and motor neurone disease, from the National Health and Medical Research Council of Australia (NHMRC) programme grant (#1037746 to GH, MK and JH) and the Australian Research Council Centre of Excellence in Cognition and its Disorders Memory Network (CE110001021 JH) and other grants/sources (NHMRC project grant #1003139). RA is a Royal Australasian College of Physicians PhD scholar and MND Research Australia PhD Scholar. MI is an ARC Discovery Early Career Researcher Award Fellow (D130100463). GH is a NHMRC Senior Principal Research Fellow (#1079679). LSTM is a NHMRC Senior Research Fellow (#1003088). No funding source had a role in the writing of the manuscript.

Competing interests

None declared.

Patient consent

No.

Provenance and peer review

Commissioned; externally peer reviewed.

Access Open

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Neurodegeneration


Neuronal network disintegration: common pathways linking neurodegenerative diseases

Rebekah M Ahmed, Emma M Devenney, Muireann Irish, Arne Ittner, Sharon Naismith, Lars M Ittner, Jonathan D Rohrer, Glenda M Halliday, Andrew Eisen, John R Hodges and Matthew C Kiernan

J Neurol Neurosurg Psychiatry published online May 12, 2016

Updated information and services can be found at: http://jnnp.bmj.com/content/early/2016/05/12/jnnp-2014-308350

These include:

References
This article cites 96 articles, 20 of which you can access for free at: http://jnnp.bmj.com/content/early/2016/05/12/jnnp-2014-308350#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (215)
Drugs: CNS (not psychiatric) (1875)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/